[Ip-health] HRC34: Intervention of the United States of America - Panel discussion on access to medicines

Mohga Kamal-Yanni mkamalyanni at Oxfam.org.uk
Fri Mar 10 05:28:47 PST 2017


Why does the US  always speaks about access to medicine as a problem for 
the rest of the world and not their own country?  Presumably they don't 
have these problems of "Inappropriate tax and tariff policies, 
insufficient health systems, inadequate access to financing, or lack of 
essential procurement systems "   or they would have implemented their own 
advice " There is nothing preventing Member States from taking immediate 
domestic action to reduce these barriers." 

Why do they behave as if everything is OK in the US? Do they read/watch 
their local news?



Best wishes for a sane, just  and peaceful 2017 مع أطيب التمنيات لعالم 
أكثر عقلا’ وعدلآ وسلامأ
____________________________
Mohga dictating to the computer so please ignore silly mistakes
Mohga Kamal-Yanni
Senior health & HIV policy advisor, Oxfam GB
Editor of www.globalhealthcheck.org
John Smith Drive, Oxford, OX4 2JY, UK (GMT, CET-1, EDT+5, EST+6)
UK Mobile   + 44 (0)777 62 55 884
Follow me @MohgaKamalYanni



From:   Thiru Balasubramaniam <thiru at keionline.org>
To:     "ip-health at lists.keionline.org" <Ip-health at lists.keionline.org>
Date:   09/03/2017 10:26
Subject:        [Ip-health] HRC34: Intervention of the United States of 
America - Panel discussion on access to medicines
Sent by:        "Ip-health" <ip-health-bounces at lists.keionline.org>


https://geneva.usmission.gov/2017/03/08/hrc-access-medicines/

*Intervention of the United States of America**Human Rights Council 34* 
*Panel discussion on access to medicines**As Delivered by Robert Waller*

*Geneva, March 8, 2017*

Thank you, Chair.

The United States believes achieving greater access to medicines, 
particularly to essential medicines, is a complex challenge.  We are 
committed to identifying practical ways to increase access to safe, 
effective, and affordable medicines around the world, and to support 
policies that drive development of new medicines, including promoting 
robust intellectual property rights protection and enforcement systems 
that provide a predictable environment in which to invest the billions of 
dollars necessary to bring life-saving drugs to market.

Regrettably, today’s panel  has failed to promote these goals as it 
focuses solely and inappropriately on advancing the recommendations of the 
report of the United Nations Secretary-General’s High-Level Panel on 
Access to Medicines.

The mandate of today’s panel was to “exchange views on good practices and 
key challenges relevant to access to medicines…taking into account all 
relevant reports.”  Unfortunately, the concept note for the panel and its 
composition suggest a focus on the HLP report that is inconsistent with 
what was agreed to in June last year.

As the United States and others have repeatedly made clear, including at 
the meeting of the World Health Organization’s Executive Board, the 
High-Level Panel operated under a flawed premise.  The HLP report 
inappropriately assumes an incoherence between access to medicines, 
intellectual property, and trade, and fails to consider critical barriers. 
The Panel could not reach consensus on its key recommendations, with two 
of the Panelists – the two who had the most extensive experience in 
research and development – warning that the Report’s recommendations could 
result in serious negative unintended consequences for R&D.  Consequently, 
today’s panel should not be used as a basis for the Human Rights Council 
to further consider the HLP report or for other future work.

This panel’s narrow focus on the HLP deprives states of the opportunity to 
consider the reasons why essential medicines that are off-patent are not 
reaching patients in some countries.  Inappropriate tax and tariff 
policies, insufficient health systems, inadequate access to financing, or 
lack of essential procurement systems  can all serve as internal barriers. 
There is nothing preventing Member States from taking immediate domestic 
action to reduce these barriers.

In closing, we request that the High Commissioner’s summary report on 
today’s panel discussion reflect the concerns we have expressed, including 
the concern that the panel’s narrow focus on  the HLP is inconsistent with 
the mandate in HRC resolution 32/15.  We look forward to continue working 
with our partners to address this and other critical issues facing our 
countries. 

Thank you
_______________________________________________
Ip-health mailing list
Ip-health at lists.keionline.org
http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org






Oxfam works with others to overcome poverty and suffering.

Oxfam GB is a member of Oxfam International and a company limited by guarantee registered in England No. 612172.
Registered office: Oxfam House, John Smith Drive, Cowley, Oxford, OX4 2JY.
A registered charity in England and Wales (no 202918) and Scotland (SC 039042)


More information about the Ip-health mailing list